NGeneBio to supply tumor RNA diagnosis products to Asan Medical Center

NGeneBio CI [Courtesy of NGeneBio]

NGeneBio, a major next-generation sequencing (NGS) diagnostic platform company, announced on Thursday that it will supply its advanced RNA precision diagnostic product, ONCOaccuPanel RNA, to Asan Medical Center in Seoul.

ONCOaccuPanel RNA was developed by NGeneBio based on technology transferred from the hospital.

This technology enables the detection of gene fusion mutations in solid tumors based on NGS, providing a highly accurate diagnostic tool for the prescription of targeted cancer therapies.

“This panel offers high accuracy in prescribing targeted cancer therapies and can detect fusion mutations across 145 genes simultaneously,” the company said. “It maintains excellent sensitivity and high accuracy and can be sequenced concurrently with the DNA solid tumor precision diagnosis panel, ONCOaccuPanel.”

This also allows for the combined analysis of DNA and RNA panels and the ability to detect a wide range of gene fusion mutations in a single test and the potential for personalized cancer treatments based on these findings are expected to maximize patient outcomes.